 Yuya Hirasawa
Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 3 | 2025 | 343 | 0.960 |
Why?
| | Veillonella | 1 | 2025 | 3 | 0.930 |
Why?
| | Streptococcus | 1 | 2025 | 29 | 0.910 |
Why?
| | Lymphocytes | 3 | 2024 | 395 | 0.910 |
Why?
| | Gastrointestinal Microbiome | 4 | 2025 | 727 | 0.700 |
Why?
| | Liver Failure, Acute | 1 | 2021 | 66 | 0.660 |
Why?
| | Cholangitis, Sclerosing | 1 | 2021 | 57 | 0.660 |
Why?
| | Lung Neoplasms | 6 | 2025 | 2568 | 0.640 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2025 | 259 | 0.620 |
Why?
| | Neoplasms | 6 | 2025 | 2761 | 0.610 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2025 | 1128 | 0.590 |
Why?
| | Neutrophils | 1 | 2024 | 1124 | 0.570 |
Why?
| | B7-H1 Antigen | 5 | 2025 | 227 | 0.560 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 859 | 0.490 |
Why?
| | Pancreatic Neoplasms | 5 | 2024 | 895 | 0.490 |
Why?
| | Aging | 1 | 2025 | 1931 | 0.430 |
Why?
| | Immunotherapy | 4 | 2025 | 649 | 0.360 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 851 | 0.330 |
Why?
| | Stomach Neoplasms | 2 | 2021 | 118 | 0.290 |
Why?
| | Aged, 80 and over | 7 | 2025 | 8020 | 0.280 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1262 | 0.280 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2021 | 193 | 0.270 |
Why?
| | CTLA-4 Antigen | 2 | 2025 | 102 | 0.270 |
Why?
| | Lymphocyte Count | 2 | 2024 | 167 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2025 | 11298 | 0.240 |
Why?
| | Aged | 14 | 2025 | 25117 | 0.240 |
Why?
| | Acetic Acid | 1 | 2025 | 21 | 0.240 |
Why?
| | Middle Aged | 14 | 2025 | 35049 | 0.240 |
Why?
| | Inosine | 1 | 2025 | 14 | 0.230 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 717 | 0.230 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2025 | 34 | 0.220 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2024 | 7 | 0.220 |
Why?
| | Feces | 2 | 2025 | 494 | 0.220 |
Why?
| | Isobutyrates | 1 | 2024 | 2 | 0.220 |
Why?
| | Esophagectomy | 1 | 2025 | 138 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1806 | 0.200 |
Why?
| | Genome, Human | 1 | 2025 | 425 | 0.200 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2024 | 207 | 0.200 |
Why?
| | Prognosis | 8 | 2025 | 4112 | 0.200 |
Why?
| | Neoplasm Staging | 3 | 2021 | 1404 | 0.190 |
Why?
| | Antigens, Neoplasm | 1 | 2025 | 321 | 0.190 |
Why?
| | Humans | 27 | 2025 | 142526 | 0.180 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 25 | 0.170 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 253 | 0.170 |
Why?
| | Monocytes | 2 | 2024 | 545 | 0.170 |
Why?
| | Male | 15 | 2025 | 70910 | 0.170 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3546 | 0.170 |
Why?
| | Prednisolone | 1 | 2021 | 68 | 0.170 |
Why?
| | Aspartate Aminotransferases | 1 | 2021 | 86 | 0.170 |
Why?
| | Female | 18 | 2025 | 76624 | 0.170 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 57 | 0.170 |
Why?
| | Alanine Transaminase | 1 | 2021 | 154 | 0.170 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2020 | 2 | 0.160 |
Why?
| | Lymphocyte Activation | 1 | 2024 | 1142 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2021 | 311 | 0.160 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2020 | 21 | 0.160 |
Why?
| | Treatment Failure | 1 | 2021 | 357 | 0.160 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 88 | 0.160 |
Why?
| | Bronchoscopy | 1 | 2021 | 227 | 0.160 |
Why?
| | Tacrolimus | 1 | 2021 | 200 | 0.160 |
Why?
| | Japan | 3 | 2025 | 134 | 0.160 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2020 | 89 | 0.150 |
Why?
| | Renal Insufficiency | 1 | 2021 | 171 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2167 | 0.150 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2022 | 258 | 0.140 |
Why?
| | Eosinophils | 1 | 2021 | 325 | 0.140 |
Why?
| | Pancreatectomy | 1 | 2021 | 265 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 255 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1453 | 0.130 |
Why?
| | Retrospective Studies | 6 | 2025 | 16626 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2024 | 2016 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 917 | 0.120 |
Why?
| | Mice | 8 | 2025 | 18172 | 0.120 |
Why?
| | Drug Synergism | 2 | 2025 | 368 | 0.100 |
Why?
| | Mutation | 1 | 2025 | 4024 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2146 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 824 | 0.090 |
Why?
| | Adult | 6 | 2025 | 39715 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1881 | 0.080 |
Why?
| | Animals | 8 | 2025 | 37697 | 0.080 |
Why?
| | Asthma | 1 | 2022 | 1914 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 914 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 1087 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1328 | 0.060 |
Why?
| | DNA, Ancient | 1 | 2025 | 8 | 0.060 |
Why?
| | History, Ancient | 1 | 2025 | 55 | 0.060 |
Why?
| | Human Migration | 1 | 2025 | 25 | 0.060 |
Why?
| | Dietary Fiber | 1 | 2025 | 57 | 0.060 |
Why?
| | Carboplatin | 1 | 2025 | 145 | 0.060 |
Why?
| | Etoposide | 1 | 2025 | 163 | 0.060 |
Why?
| | ADAM17 Protein | 1 | 2024 | 36 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 175 | 0.050 |
Why?
| | Tumor Escape | 1 | 2024 | 47 | 0.050 |
Why?
| | Genetics, Population | 1 | 2025 | 212 | 0.050 |
Why?
| | Fluorouracil | 1 | 2025 | 208 | 0.050 |
Why?
| | Prospective Studies | 3 | 2021 | 7862 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 60 | 0.050 |
Why?
| | Acidaminococcus | 1 | 2023 | 1 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5967 | 0.050 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2025 | 212 | 0.050 |
Why?
| | Cisplatin | 1 | 2025 | 328 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2025 | 431 | 0.050 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 30 | 0.050 |
Why?
| | Mice, Inbred BALB C | 1 | 2025 | 1267 | 0.050 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2021 | 16 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 548 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2025 | 451 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5270 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2024 | 394 | 0.040 |
Why?
| | Area Under Curve | 1 | 2021 | 326 | 0.040 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 19 | 0.040 |
Why?
| | Capecitabine | 1 | 2020 | 42 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2020 | 251 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2020 | 328 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 453 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2020 | 270 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1053 | 0.040 |
Why?
| | HeLa Cells | 1 | 2020 | 644 | 0.030 |
Why?
| | Pancreas | 1 | 2020 | 333 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 566 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2020 | 337 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 922 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 771 | 0.030 |
Why?
| | Bacteria | 1 | 2024 | 881 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2053 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1995 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 546 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3362 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2022 | 1124 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2081 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4483 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2927 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1773 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 5994 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2828 | 0.020 |
Why?
| | Biomarkers | 1 | 2024 | 4207 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2272 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2831 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3562 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7006 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 10593 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 22326 | 0.010 |
Why?
|
|
Hirasawa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|